



US007818854B2

(12) **United States Patent**  
**Wilson**

(10) **Patent No.:** **US 7,818,854 B2**  
(45) **Date of Patent:** **Oct. 26, 2010**

(54) **ULTRASOUND RADIATING MEMBERS FOR CATHETER**

4,040,414 A 8/1977 Suroff  
4,319,580 A 3/1982 Colley et al.  
4,354,502 A 10/1982 Colley et al.

(75) Inventor: **Richard R. Wilson**, Seattle, WA (US)

(73) Assignee: **Ekos Corporation**, Bothell, WA (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(Continued)

FOREIGN PATENT DOCUMENTS

DE 39 19 592 A1 2/1990

(21) Appl. No.: **12/371,544**

(22) Filed: **Feb. 13, 2009**

(65) **Prior Publication Data**

US 2009/0144955 A1 Jun. 11, 2009

**Related U.S. Application Data**

(62) Division of application No. 11/143,518, filed on Jun. 2, 2005, now Pat. No. 7,509,715, which is a division of application No. 10/684,845, filed on Oct. 14, 2003, now Pat. No. 6,921,371.

(60) Provisional application No. 60/418,400, filed on Oct. 14, 2002.

(51) **Int. Cl.**  
**H04R 17/10** (2006.01)

(52) **U.S. Cl.** ..... **29/25.35**; 29/594; 29/847;  
29/417; 310/368

(58) **Field of Classification Search** ..... 29/25.35,  
29/594, 847, 852; 600/466; 601/2; 604/22;  
310/320, 348, 368

See application file for complete search history.

(56) **References Cited**


**U.S. PATENT DOCUMENTS**

2,752,662 A \* 7/1956 Crooks et al. .... 29/25.35  
2,961,382 A 11/1960 Singher et al.  
3,443,226 A 3/1969 Boyd  
3,565,062 A 2/1971 Kuris  
3,596,335 A \* 8/1971 Bennett ..... 29/25.35  
4,027,659 A 6/1977 Slingluff

(57) **ABSTRACT**

A method comprises providing a substantially planar slab of piezoelectric material having a top surface. The method further comprises drilling a plurality of holes through the top surface and into the slab. The method further comprises making a plurality of cuts through the top surface and into the slab. The cuts form a plurality of polygons that are generally centered about one of the holes. The method further comprises plating the slab with an electrically conductive material. The method further comprises removing the electrically conductive material from the top surface of the slab. The method further comprises cutting the slab substantially parallel to the top surface.

**7 Claims, 25 Drawing Sheets**



U.S. PATENT DOCUMENTS			5,342,292 A	8/1994	Nita et al.
			5,344,395 A <td>9/1994<td>Whalen et al.</td></td>	9/1994 <td>Whalen et al.</td>	Whalen et al.
4,398,325 A	8/1983	Piaget et al.	5,344,435 A	9/1994	Turner et al.
4,466,442 A	8/1984	Hilmann et al.	5,345,940 A	9/1994	Seward et al.
4,512,762 A	4/1985	Spears	5,353,798 A	10/1994	Sieben
4,531,943 A	7/1985	Van Tassel et al.	5,354,279 A	10/1994	Hofling
4,573,470 A	3/1986	Samson et al.	5,362,309 A	11/1994	Carter
4,582,067 A	4/1986	Silverstein et al.	5,363,853 A	11/1994	Lieber
4,628,223 A	12/1986	Takeuchi et al.	5,368,036 A	11/1994	Tanaka et al.
4,657,543 A	4/1987	Langer et al.	5,380,273 A	1/1995	Dubrul et al.
4,657,756 A	4/1987	Rasor et al.	5,390,678 A	2/1995	Gesswein et al.
4,692,139 A	9/1987	Stiles	5,399,158 A	3/1995	Lauer et al.
4,698,058 A	10/1987	Greenfeld et al.	5,415,636 A	5/1995	Forman
4,710,192 A	12/1987	Liotta et al.	5,419,763 A	5/1995	Hildebrand
4,750,902 A	6/1988	Wuchinich et al.	5,421,338 A	6/1995	Crowley et al.
4,762,915 A	8/1988	Kung et al.	5,423,797 A	6/1995	Adrian et al.
4,767,402 A	8/1988	Kost et al.	5,431,663 A	7/1995	Carter
4,772,594 A	9/1988	Hashimoto et al.	5,445,155 A	8/1995	Sieben
4,774,958 A	10/1988	Feinstein	5,447,509 A	9/1995	Mills et al.
4,780,212 A	10/1988	Kost et al.	5,458,568 A	10/1995	Racchini et al.
4,797,285 A	1/1989	Barenholz et al.	5,465,726 A	11/1995	Dickenson et al.
4,808,153 A	2/1989	Parisi	5,474,530 A	12/1995	Passafaro et al.
4,821,740 A	4/1989	Tachibana et al.	5,474,531 A	12/1995	Carter
4,844,882 A	7/1989	Widder et al.	5,489,279 A	2/1996	Meserol
4,870,953 A	10/1989	Don Michael et al.	5,498,238 A	3/1996	Shapland et al.
4,877,031 A	10/1989	Conway et al.	5,509,896 A	4/1996	Carter
4,900,540 A	2/1990	Ryan et al.	5,514,092 A	5/1996	Forman et al.
4,917,088 A	4/1990	Crittendon	5,520,189 A	5/1996	Malinowski et al.
4,917,102 A	4/1990	Miller et al.	5,542,935 A	8/1996	Unger et al.
4,920,954 A	5/1990	Alliger et al.	5,558,092 A	9/1996	Unger et al.
4,924,863 A	5/1990	Sterzer	5,558,642 A	9/1996	Schweich, Jr. et al.
4,936,281 A	6/1990	Stasz	5,567,687 A	10/1996	Magda et al.
4,948,587 A	8/1990	Kost et al.	5,569,198 A	10/1996	Racchini
4,953,565 A	9/1990	Tachibana et al.	5,580,575 A	12/1996	Unger et al.
4,955,863 A	9/1990	Walker et al.	5,585,112 A	12/1996	Unger et al.
4,971,991 A	11/1990	Umemura et al.	5,586,982 A	12/1996	Abela
4,992,257 A	2/1991	Bonnett et al.	5,588,962 A	12/1996	Nicholas et al.
5,007,898 A	4/1991	Rosenbluth et al.	5,594,136 A	1/1997	Sessler et al.
5,021,044 A	6/1991	Sharawy	5,599,923 A	2/1997	Sessler et al.
5,040,537 A	8/1991	Katakura	5,603,327 A	2/1997	Eberle
5,053,044 A	10/1991	Mueller et al.	5,606,974 A	3/1997	Castellano et al.
5,069,664 A	12/1991	Guess et al.	5,609,574 A	3/1997	Kaplan et al.
5,081,993 A	1/1992	Kitney	5,616,342 A	4/1997	Lyons
5,085,662 A	2/1992	Willard	5,617,851 A	4/1997	Lipkovker
5,117,831 A	6/1992	Jang et al.	5,618,275 A	4/1997	Bock
5,149,319 A	9/1992	Unger	5,620,479 A	4/1997	Diederich
5,156,050 A	10/1992	Schmid et al.	5,628,728 A	5/1997	Tachibana et al.
5,158,071 A	10/1992	Umemura et al.	5,628,730 A	5/1997	Shapland
5,163,421 A	11/1992	Bernstein et al.	5,630,837 A	5/1997	Crowley
5,164,920 A	11/1992	Bast et al.	5,632,970 A	5/1997	Sessler et al.
5,181,920 A	1/1993	Mueller et al.	5,648,098 A	7/1997	Porter
5,190,766 A	3/1993	Ishihara	5,660,180 A	8/1997	Malinowski et al.
5,197,946 A	3/1993	Tachibana	5,663,327 A	9/1997	Tarabo et al.
5,209,720 A	5/1993	Unger	5,695,460 A	12/1997	Siegel et al.
5,215,680 A	6/1993	D'Arrigo	5,707,608 A	1/1998	Liu
5,216,130 A	6/1993	Line et al.	5,713,848 A	2/1998	Dubrul et al.
5,250,034 A	10/1993	Appling et al.	5,718,921 A	2/1998	Mathiowitz et al.
5,267,954 A	12/1993	Nita	5,725,494 A	3/1998	Briskin
5,267,985 A	12/1993	Shimada et al.	5,733,572 A	3/1998	Unger et al.
5,269,291 A	12/1993	Carter	5,735,811 A	4/1998	Briskin
5,269,297 A	12/1993	Weng et al.	5,766,902 A	6/1998	Craig et al.
5,277,913 A	1/1994	Thompson et al.	5,770,222 A	6/1998	Unger et al.
5,279,546 A	1/1994	Mische et al.	5,776,429 A	7/1998	Unger et al.
5,282,785 A	2/1994	Shapland et al.	5,779,673 A	7/1998	Roth et al.
5,286,254 A	2/1994	Shapland et al.	5,817,048 A	10/1998	Lawandy
5,295,484 A	3/1994	Marcus et al.	5,836,896 A	11/1998	Rosenschein
5,304,115 A	4/1994	Pflueger et al.	5,846,218 A	12/1998	Briskin et al.
5,315,998 A	5/1994	Tachibana et al.	5,849,727 A	12/1998	Porter et al.
5,318,014 A	6/1994	Carter	5,876,989 A	3/1999	Berg et al.
5,323,769 A	6/1994	Bommannan et al.	5,895,356 A	4/1999	Andrus
5,324,255 A	6/1994	Passafaro et al.	5,895,398 A	4/1999	Wensel et al.
5,327,891 A	7/1994	Rammner	5,916,192 A	6/1999	Nita et al.
5,328,470 A	7/1994	Nabel et al.	5,922,687 A	7/1999	Mann et al.

5,925,016 A	7/1999	Chornenky et al.	2007/0265560 A1	11/2007	Soltani et al.
5,938,595 A	8/1999	Glass et al.	FOREIGN PATENT DOCUMENTS		
5,941,868 A	8/1999	Kaplan et al.	DE	40 05 743	8/1991
5,997,497 A	12/1999	Nita et al.	EP	0 189 329	7/1986
6,001,069 A	12/1999	Tachibana et al.	EP	0 529 675	8/1992
6,024,718 A	2/2000	Chen et al.	EP	0 629 382	11/1993
6,030,374 A	2/2000	McDaniel	EP	668052 A2	2/1995
6,068,857 A	5/2000	Weitschies et al.	EP	1 252 885	10/2002
6,078,830 A	6/2000	Levin et al.	JP	61048984 *	3/1986
6,096,000 A	8/2000	Tachibana et al.	JP	2-180275	7/1990
6,096,070 A	8/2000	Ragheb et al.	WO	WO 89/05160	6/1989
6,110,314 A	8/2000	Nix et al.	WO	WO 91/09629	7/1991
6,113,558 A	9/2000	Rosenschein et al.	WO	WO 92/07622	5/1992
6,117,858 A	9/2000	Porter et al.	WO	WO 93/08738	5/1993
6,135,976 A	10/2000	Tachibana et al.	WO	WO 94/05361	3/1994
6,176,842 B1	1/2001	Tachibana et al.	WO	WO 95/01751	1/1995
6,210,356 B1	4/2001	Anderson et al.	WO	WO 95/15118	6/1995
6,210,393 B1	4/2001	Briskin	WO	WO 96/07432	3/1996
6,228,046 B1	5/2001	Briskin	WO	WO 96/15815	5/1996
6,238,347 B1	5/2001	Nix et al.	WO	WO 96/27341	9/1996
6,245,747 B1	6/2001	Porter et al.	WO	WO 96/29935	10/1996
6,287,271 B1	9/2001	Dubrul et al.	WO	WO 96/35469	11/1996
6,295,990 B1	10/2001	Lewis et al.	WO	WO 96/36286	11/1996
6,296,619 B1	10/2001	Briskin et al.	WO	WO 97/19645	6/1997
6,312,402 B1	11/2001	Hansmann	WO	WO 98/11826	3/1998
6,346,098 B1	2/2002	Yock et al.	WO	WO 89/04142	5/1998
6,361,500 B1	3/2002	Masters	WO	WO 98/48711	11/1998
6,361,531 B1	3/2002	Hissong	WO	WO 98/58699	12/1998
6,372,498 B2	4/2002	Newman et al.	WO	WO 99/25385	5/1999
6,384,516 B1	5/2002	Fraser	WO	WO 99/33500	7/1999
6,416,740 B1	7/2002	Unger	WO	WO 99/34858	7/1999
6,425,853 B1	7/2002	Edwards	WO	WO 99/39738	8/1999
6,437,487 B1	8/2002	Mohe et al.	WO	WO 00/38580	7/2000
6,461,296 B1	10/2002	Desai	WO	WO 01/53009	7/2001
6,461,383 B1	10/2002	Gesswein et al.	WO	WO 03/007649	1/2003
6,503,204 B1	1/2003	Sumanaweera et al.	OTHER PUBLICATIONS		
6,508,775 B2	1/2003	McKenzie et al.	Anderson, <i>Human gene therapy</i> . (Nature 392:25-30, 1998).		
6,508,816 B2	1/2003	Shaddock	Bao, et al. "Transfection of a Reporter Plasmid into Cultured Cells by Sonoporation in Vitro," <i>Ultrasound in Med. and Biol.</i> , vol. 23, No. 6, pp. 953, 1997.		
6,524,251 B2	2/2003	Rabiner et al.	Bleeker et al., <i>J. Ultrasound, Med.</i> 9(8): 461-71 (Aug. 1990) On the Application of Ultrasonic Contrast Agents for Blood Flowmetry and Assessment of Cardiac Perfusion.		
6,527,761 B1	3/2003	Soltész et al.	Branch, <i>A Good Antisense Molecule is Hard to Find</i> , (Trends in Biochem Sci 23: 45-50, 1998).		
6,548,047 B1	4/2003	Unger	B.D. Butler, <i>J. clin. Ultrasound</i> 14(5): 408-12 (Jun. 1986) Production of Microbubbles for Use as Echo Contrast Agents.		
6,551,337 B1	4/2003	Rabiner et al.	Cancer Letters, vol. 72, 1993, pp. 195-199.		
6,582,392 B1	6/2003	Bennett et al.	Cancer Letters, vol. 78 (1-3), 1994, pp. 177-181.		
6,652,581 B1	11/2003	Ding	Crooke, <i>Basic Principles of Antisense Therapeutics</i> (Springer-Verlag, Eds, New York, 1998, pp. 1 and 4).		
6,660,013 B2	12/2003	Rabiner et al.	Fechmeier, et al. "Transfection of Mammalian Cells with Plasmid DNA by Scrape Loading and Sonication Loading," <i>Proc. Natl. Acad. Sci. USA</i> , vol. 84, pp. 8463-8467, Dec. 1987.		
6,680,301 B2	1/2004	Berg et al.	Feinstein et al., <i>J. Am. Coll. Cardiol.</i> 3(1): 14-20 (Jan. 1984) Two-dimensional Contrast Echocardiography I. In Vitro Development and Quantitative Analysis of Echo Contrast Agents.		
6,723,063 B1	4/2004	Zhang et al.	Feldman, et al. "Optimal Techniques for Arterial Gene Transfer," <i>Cardiovascular Research</i> , 35 (1997) pp. 391-404.		
6,794,369 B2	9/2004	Newman et al.	Greenleaf, William J. et al.; <i>Artificial Cavitation Nuclei Significantly Enhance Acoustically Induced Cell Transfection</i> . vol. 24, No. 4 pp. 587-595, 1998.		
6,921,371 B2	7/2005	Wilson	Ho and Parkinson, <i>Antisense Oligonucleotides and Therapeutics for Malignant Diseases</i> , (Seminars in Drug Discovery 24(2): 187-202, 1997).		
6,958,040 B2	10/2005	Oliver et al.	Holland, C.K. and R.E. Apfel, <i>J. Acoust. Soc. Am.</i> 88(5): 2059-2069 (Nov. 1990) Thresholds for Transient Cavitation Produced by Pulsed Ultrasound in a Controlled Nuclei Environment.		
6,958,059 B2	10/2005	Zadno-Azizi	Hynynen et al.; "Small Cylindrical Ultrasound Sources For Induction of Hyperthermia via Body Cavities or Interstitial Implants"; <i>Arizona</i>		
6,797,293 B2	12/2005	Hansmann et al.			
7,141,044 B2	11/2006	Gentsler			
2001/0003790 A1	6/2001	Ben-Haim et al.			
2001/0007666 A1	7/2001	Hoffman et al.			
2001/0053384 A1	12/2001	Greenleaf et al.			
2002/0032394 A1	3/2002	Briskin et al.			
2002/0055731 A1	5/2002	Atala et al.			
2002/0068717 A1	6/2002	Borrelli			
2002/0099356 A1	7/2002	Unger et al.			
2002/0151792 A1	10/2002	Conston et al.			
2003/0040501 A1	2/2003	Newman et al.			
2003/0069525 A1	4/2003	Briskin et al.			
2004/0015084 A1	1/2004	Flesch et al.			
2004/0024347 A1	2/2004	Wilson et al.			
2004/0034306 A1	2/2004	Seward			
2004/0039329 A1	2/2004	Ueberle			
2004/0106841 A1	6/2004	Shaw et al.			
2005/0027247 A1	2/2005	Carrison et al.			
2005/0091833 A1 *	5/2005	Kiepen et al. .... 29/594			
2005/0197619 A1	9/2005	Rule et al.			

- Cancer Center and Department of Radiation Oncology, University of Arizona Health Sciences Center*; vol. 9, No. 2; pp. 263-274; 1993.
- Japanese Journal of Cancer Research, vol. 81, No. 3, Mar. 1990, pp. 304-308.
- Jeffers, Russel et al.; Dimethylformamide as an Enhancer of Cavitation-Induced Cell Lysis In Vitro, vol. 97, No. 1, Jan. 1995.
- Jeffers, R.J. et al.; Evaluation of the Effect of Cavitation Activity on Drug-Ultrasound Synergisms, 1993.
- Keller et al., J. Ultrasound Med. 5(9): 493-8 (Sep. 1986) Automated Production and Analysis of Echo Contrast Agents.
- Kim, et al. "Ultra-sound Mediated Transfection of Mammalian Cells," Human Gene Therapy, 7: 1339-1346 (Jul. 10, 1996).
- Kim, T.F. Medical news & Perspectives, JAMA 261(11): 1542 (Mar. 17, 1989) Microbubbles Show Promise for Enhancing Ultrasound Signal, Image, Other Applications.
- Kotnis, et al. "Optimisation of Gene Transfer into Vascular Endothelial Cells Using Electroporation," Eur J. Vasc Surg, 9, 71-79 (1995).
- Lang et al., Circulation 75(1): 229-234 (Jan. 1987) Contrast Ultrasonography of the Kidney: a New Method for Evaluation of Renal Perfusion in Vivo.
- Lee et al.; "Arrays of Multielement Ultrasound Applicators For Interstitial Hyperthermia"; IEEE Transactions on biomedical Engineering; vol. 46, No. 7; Jul. 1999.
- Leong et al., Biomaterials, vol. 7: 364-371 (Sep. 1986) Polyanhydrides for Controlled Release of Bioactive Agents.
- G. Maywald et al., "Experience With Atraumatic Vascular Diagnosis With the Aid of the Ultrasonic Doppler Technique", Electromedica, vol. 2 pp. 43-48 (1976).
- Meltzer et al., J. Clin. Ultrasound 8(2): 121-7 (Apr. 1980) The Source of Ultrasound Contrast Effect.
- Miller, Douglas L. et al.; Sonoporation of Cultured Cells in the Rotation Tube Exposure System, vol. 25, No. 1, 1999.
- Orkin and Motulsky, Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, (p. 1-38, Dec. 7, 1995).
- PCT Search Report, PCT Application PCT/US2006/13531; Apr. 12, 2006.
- Porter, et al "Interaction of Diagnostic Ultrasound with Synthetic Oligonucleotide-Labeled Perfluorocarbon-Exposed Sonicated Dextrose Albumin Microbubbles," J Ultrasound Med, 15:557-584, 1996.
- Porter, T.R. et al., Thrombolytic Enhancement With Perfluorocarbon-Exposed Sonicated Dextrose Albumin Microbubbles, Nov. 1996.
- Prat, F. et al.; In Vivo Effects of Cavitation Alone or in Combination With Chemotherapy in a Peritoneal Carcinomatosis in the Rat. vol. 68, pp. 13-17, 1993.
- Price, Richard et al.; Delivery of Colloidal Particles and Red Blood Cells to Tissue Through Microvessel Ruptures Created by Targeted Microbubble Destruction With Ultrasound, Sep. 29, 1998.
- Romano et al., Latest Developments in Gene Transfer Technology: Achievements, Perspectives, and Controversies over Therapeutic Applications, (Stem Cells 18: 19-39, 2000).
- Rosenschein, U. et al., Experimental Ultrasonic Angioplasty: Disruption of Atherosclerotic Plaques and Thrombi In Vitro and Arterial Recanalization in, 1990.
- Somia and Verma, Gene Therapy: Trials and Tribulations, (Nature Reviews Genetics 1:91-99, 2000).
- Tachibana, K. "Enhancement of Fibrinolysis with Ultrasound Energy", JVIR, vol. 3, No. 2, May 1992, pp. 299-303.
- Tachibana K.; Albumin Microbubble Echo-Contrast Materials as an Enhancer for Ultrasound Accelerated Thrombolysis, Sep. 1, 1995.
- Tsurumi, et al. "Direct Intramuscular Gene Transfer of Naked DNA Encoding Vascular Endothelial Growth Factor Augments Collateral Development and Tissue Perfusion," Circulation, 1996; 94: 3281-3290.
- Unger, et al. "Ultrasound Enhances Gene Expression of Liposomal Transfection," Investigative Radiology, vol. 32, No. 12, pp. 723-727, 1997.
- Unger, Evan C. et al.; Acoustically Active Liposomes Containing Paclitaxel, vol. 11, No. 12, 1992.
- Vandenburg et al., Am. Heart J., 115(4), 733-9 (Apr. 1988) Myocardial Risk Area and Peak Gray Level Measurement by Contrast Echocardiography: Effect of Microbubble Size and Concentration, Injection Rate, and Coronary Vasodilation.
- Verma et al., Gene Therapy—promises, problems and prospects, (Nature 389: 239-242, 1997).
- Wheatly et al., Biomaterials 11(19): 713-7 (Nov. 1990) Contrast Agents for Diagnostic Ultrasound: Development and Evaluation of Polymer-Coated Microbubbles.
- Wu, Yunqiu et al., Binding and Lysing of Blood Clots Using MRX-408, May 1998.
- Wyber, et al. "The Use of Sonication for the Efficient Delivery of Plasmid DNA into Cells," Pharmaceutical Research, vol. 14, No. 6, pp. 750-756, 1997.
- PCT Search Report, PCT Application PCT/US2008/86713; Dec. 12, 2008.

\* cited by examiner





FIG. 1



**FIG. 2A**




FIG. 2B




FIG. 3A




FIG. 3B




FIG. 3C






FIG. 4A





FIG. 4B







FIG. 5E





FIG. 5F






FIG. 6A




FIG. 6B




FIG. 7




FIG. 8A

FIG. 8B





FIG. 8C



*FIG. 9*






FIG. 10





*FIG. 11A*



*FIG. 11B*







FIG. 11C











**FIG. 11E.**




**FIG. 11F.**





**FIG. 11G**


*FIG. 12A**FIG. 12B**FIG. 12C**FIG. 12D**FIG. 12E*





*FIG. 13*

*FIG. 14*

*FIG. 15A*

*FIG. 15B*

*FIG. 16**FIG. 17*

# ULTRASOUND RADIATING MEMBERS FOR CATHETER

## PRIORITY APPLICATION

This application is a divisional of U.S. patent application Ser. No. 11/143,518 (filed Jun. 2, 2005), which is a divisional of U.S. patent application Ser. No. 10/684,845 (filed 14 Oct. 2003) now U.S. Pat. No. 6,921,371, which claims the benefit of U.S. Provisional Patent Application 60/418,400 (filed 14 Oct. 2002). All of these priority applications are hereby incorporated by reference herein in their entirety.

## FIELD OF THE INVENTION

The present invention relates generally to ultrasound radiating members, and relates more specifically to ultrasound radiating members configured for use in medical applications to enhance the delivery and/or effect of a therapeutic compound.

## BACKGROUND OF THE INVENTION

Several therapeutic and diagnostic applications in the medical field use ultrasonic energy. For example, ultrasonic energy can be used to enhance the delivery and/or effect of various therapeutic compounds. See, for example, U.S. Pat. Nos. 4,821,740, 4,953,565 and 5,007,438. In some applications, a catheter delivers ultrasonic energy and a therapeutic compound to a specific treatment site within the body. Such a catheter typically includes an ultrasonic assembly for generating the ultrasonic energy and a delivery lumen for delivering the therapeutic compound to the treatment site. Using this device, sometimes referred to as an "ultrasonic catheter," the ultrasonic energy can be applied at the treatment site to enhance the therapeutic effect and/or the delivery of the therapeutic compound.

Ultrasonic catheters have successfully been used to treat human blood vessels that have become occluded or completely blocked by plaque, thrombi, emboli or other substances that reduce the blood carrying capacity of the vessel. See, for example, U.S. Pat. No. 6,001,069. To remove the blockage, solutions containing dissolution compounds can be delivered directly to the blockage site using an ultrasonic catheter. In this design, ultrasonic energy generated by the catheter enhances the delivery and/or therapeutic effect of the dissolution compounds.

Ultrasonic catheters can also be used to perform gene therapy on an isolated region of a body lumen. For example, as disclosed in U.S. Pat. No. 6,135,976, an ultrasonic catheter can be provided with one or more expandable sections for occluding a section of the body lumen. A gene therapy composition can then be delivered to the occluded section through a delivery lumen. Ultrasonic energy is then delivered to the occluded section to enhance the entry of the gene therapy composition into the cells of the occluded section.

Another use for an ultrasonic catheter is the delivery and activation of light activated drugs, as disclosed in U.S. Pat. No. 6,176,842. Additionally, ultrasound-enhanced thrombolytic therapy can be used to dissolve blood clots in arteries and veins in the treatment of conditions such as peripheral arterial occlusion and deep vein thrombosis. In such applications, an ultrasonic catheter delivers ultrasonic energy into a vessel, where the ultrasonic energy enhances thrombolysis with agents such as urokinase, tissue plasminogen activator ("TPA") and others.

## SUMMARY OF THE INVENTION

Conventional ultrasonic assemblies include one or more ultrasound radiating members, which usually have a cylindrical or rectangular geometry. Cylindrical ultrasound radiating members are often difficult to manufacture and can be subject to mechanical failure. Rectangular ultrasound radiating members are easier to manufacture but Applicant has determined that they produce a less radially uniform distribution of ultrasound energy. Thus, an ultrasound radiating member having an improved manufacturing process, improved durability and with a more radially uniform distribution of ultrasound energy has been developed.

In accordance with one embodiment of the present invention, an ultrasound radiating member comprising a front face and a rear face. Each face has  $n$  sides, wherein  $n$  is greater than 4. The ultrasound radiating member further comprises  $n$  faces connecting the sides of the front and rear faces. The ultrasound radiating member further comprises a central bore extending from the front face to the rear face.

In accordance with another embodiment of the present invention, an ultrasound catheter comprises a tubular member. the ultrasound catheter further comprises at least one ultrasound radiating member positioned with the tubular member. The ultrasound radiating member comprises a front face and a rear face. Each face has  $n$  sides, wherein  $n$  is greater than 4. The ultrasound radiating member further comprises  $n$  faces connecting the sides of the front and rear faces. the ultrasound radiating member further comprises a central bore extending from the front face to the rear face. At least a portion of the surfaces of the inner bore and  $n$  faces are coated with a conductive material. The ultrasound catheter further comprises a first wire and a second wire. The first wire is connected to the inner bore, and the second wire is connected to at least one of the  $n$  faces.

In accordance with another embodiment of the present invention, a method for manufacturing an ultrasonic radiating member comprises providing a sheet of piezoelectric material. The method further comprises drilling a plurality of holes into the piezoelectric material. Each hole has an inner surface. The method further comprises making a plurality of cuts into the sheet. Each cut has a depth less than the depth of the holes. The cuts form an elongate polygon that is generally centered about one of the holes. The polygon has an outer surface. The method further comprises plating at least a portion of the inner and outer surfaces with a conductive material. The method further comprises cutting a backside from the sheet so as to separate individual elongate polygons.

In accordance with another embodiment of the present invention, an apparatus comprises an elongate ultrasound radiating member having a hollow, cylindrical central core and three or more substantially flat sides. The apparatus further comprises a first cylindrical electrode applied to the hollow, cylindrical central core. The apparatus further comprises a second electrode applied to at least one of the sides.

In accordance with another embodiment of the present invention, a method comprises providing a substantially planar slab of piezoelectric material having a top surface. The method further comprises drilling a plurality of holes through the top surface and into the slab. The method further comprises making a plurality of cuts through the top surface and into the slab. The cuts form a plurality of polygons that are generally centered about one of the holes. The method further comprises plating the slab with an electrically conductive material. The method further comprises removing the elec-

trically conductive material from the top surface of the slab. The method further comprises cutting the slab substantially parallel to the top surface.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Exemplary embodiments of the ultrasound radiating members disclosed herein, and certain applications therefor, are illustrated in the accompanying drawings, which are for illustrative purposes only. The drawings comprise the following figures, in which like numerals indicate like parts.

FIG. 1 is a side view of an ultrasonic catheter that is particularly well-suited for use in small vessels of the distal anatomy.

FIG. 2A is a cross-sectional view of the distal end of the ultrasonic catheter of FIG. 1.

FIG. 2B is a cross-sectional view of the ultrasonic catheter of FIG. 2A taken through line 2B-2B.

FIG. 3A is side elevation view of one embodiment of an ultrasonic catheter which is particularly well-suited for treating long segment peripheral arterial occlusions, such as those occasionally found in the arteries of the leg.

FIG. 3B is a side elevation view of an inner core configured for use with the ultrasonic catheter of FIG. 3A.

FIG. 3C is a side elevation view of a modified embodiment of an ultrasonic catheter.

FIG. 4A is a cross-sectional view of a distal end of the ultrasonic catheter of FIG. 3A.

FIG. 4B is a cross-sectional view of a proximal end of the ultrasonic catheter of FIG. 3A.

FIG. 4C is a cross-sectional view of another modified embodiment of an ultrasonic catheter.

FIG. 5A is a side view of the distal end of the ultrasonic catheter of FIG. 3A.

FIG. 5B is a cross-sectional view of the distal end of the ultrasonic catheter of FIG. 5A taken through line 5B-5B.

FIG. 5C is a side view of a modified embodiment of the distal end of an ultrasonic catheter.

FIG. 5D is a cross-sectional view of the distal end of the ultrasonic catheter of FIG. 5C taken along line 5D-5D.

FIG. 5E is a side view of another modified embodiment of the distal end of an ultrasonic catheter.

FIG. 5F is a side view yet of another modified embodiment of the distal end of an ultrasonic catheter.

FIG. 6A is a side view of yet another modified embodiment of the distal end of an ultrasonic catheter which includes drug delivery ports of increasing size.

FIG. 6B is a cross-sectional view of the distal end of an ultrasonic catheter wherein the proximal and distal ends are made of different materials.

FIG. 7 is a cross-sectional view of a distal end of an ultrasonic catheter that includes an integral occlusion device.

FIG. 8A illustrates a wiring diagram for connecting a plurality of ultrasound radiating members in parallel.

FIG. 8B illustrates a wiring diagram for connecting a plurality of ultrasound radiating members in series.

FIG. 8C illustrates a wiring diagram for connecting a plurality of ultrasound radiating members with a common wire.

FIG. 9 is a wiring diagram for connecting a plurality of temperature sensors with a common wire.

FIG. 10 is a block diagram of a feedback control system for use with an ultrasonic catheter

FIG. 11A is a cross-sectional view of a treatment site.

FIG. 11B is a side view of the distal end of an ultrasonic catheter positioned at the treatment site.

FIG. 11C is a cross-sectional view of the distal end of the ultrasonic catheter of FIG. 11B positioned at the treatment site.

FIG. 11D is a side view of the proximal end of the ultrasonic catheter of FIG. 11B.

FIG. 11E is a cross-sectional view of the distal end of the ultrasonic catheter of FIG. 11B positioned at the treatment site.

FIG. 11F is a cross-sectional view of the distal end of the ultrasonic catheter of FIG. 11B positioned at the treatment site showing the movement of the inner core.

FIG. 11G is a side view of the distal end of the ultrasonic catheter of FIG. 11B positioned at the treatment site.

FIG. 12A is a perspective view of an ultrasound radiating member having pentagonal front and rear faces.

FIG. 12B is a perspective view of an ultrasound radiating member having hexagonal front and rear faces.

FIG. 12C is a perspective view of an ultrasound radiating member having octagonal front and rear faces.

FIG. 12D is a perspective view of an ultrasound radiating member having triangular front and rear faces.

FIG. 12E is a perspective view of an ultrasound radiating member having rectangular front and rear faces.

FIG. 13 is a perspective view of an ultrasound radiating member having first and second wires connected to inner and outer surfaces, respectively.

FIG. 14 is a perspective view of a sheet of piezoelectric material perforated with through or blind holes.

FIG. 15A is a plan view of the piezoelectric sheet of FIG. 14 having been cut to produce ultrasound radiating members having a hexagonal geometry.

FIG. 15B is a plan view of the piezoelectric sheet of FIG. 14 having been cut to produce ultrasound radiating members having an octagonal geometry.

FIG. 16 is a cross-sectional view of the cut piezoelectric sheet of FIG. 15A or 15B.

FIG. 17 is a cross-sectional view of the piezoelectric sheet of FIG. 16, illustrating a method of harvesting individual ultrasound radiating members.

#### DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

##### Introduction

Certain exemplary embodiments described herein relate to ultrasonic catheters and methods of using ultrasonic catheters. As described above, ultrasonic catheters can be used to enhance the effect and/or delivery of a therapeutic compound. As used herein, the term "therapeutic compound" refers, in addition to its ordinary meaning, to drugs, biological macromolecules (including, but not limited to, proteins and nucleic acids), and other pharmacological agents, including combinations thereof. Exemplary applications of ultrasonic catheters are provided in U.S. Pat. Nos. 5,318,014, 5,362,309, 5,474,531, 5,628,728, 6,001,069, and 6,210,356.

In one exemplary embodiment, an ultrasonic catheter is adapted for use in the treatment of thrombus in the small blood vessels or arteries of the human body, such as, for example, the small cerebral arteries. In another embodiment, an ultrasonic catheter is adapted for use in the treatment of thrombus in larger blood vessels or arteries of the human body such as those located in the lower leg. In still other embodiments, the ultrasonic catheters disclosed herein can also be used in other therapeutic applications, such as performing gene therapy (see, for example, U.S. Pat. No. 6,135,976), activating light activated drugs used to cause targeted tissue

death (see, for example, U.S. Pat. No. 6,176,842) and causing cavitation to produce biological effects (see, for example, U.S. Pat. No. RE36,939). Moreover, such therapeutic applications may be used in various human tissues, such as other parts of the circulatory system, solid tissues, duct systems and body cavities. Certain embodiments of the ultrasonic catheters disclosed herein can also be used in other medical applications, such as diagnostic and imaging applications.

In exemplary embodiments, the ultrasonic catheters disclosed herein can be used in applications where the ultrasonic energy provides a therapeutic effect by itself. For example, in certain applications, ultrasonic energy can provide and/or reduce stenosis and/or restenosis; tissue ablation, abrasion or disruption; promotion of temporary or permanent physiological changes in intracellular or intercellular structures; and/or rupture of micro-balloons or micro-bubbles for therapeutic compound delivery. See, for example, U.S. Pat. Nos. 5,269,291 and 5,431,663. The methods and apparatuses disclosed herein can also be used in applications that do not require the use of a catheter, such as, enhancement of hyperthermic drug treatment, use of externally generated ultrasonic energy to enhance the effect and/or delivery of a therapeutic compound at a specific site within the body, and use of ultrasonic energy to provide a therapeutic or diagnostic effect by itself. See, for example, U.S. Pat. Nos. 4,821,740, 4,953,565, 5,007,438 and 6,096,000.

The term "ultrasonic energy" is used broadly, and encompasses its ordinary definition, as well as mechanical energy transferred through longitudinal pressure or compression waves with a frequency greater than about 20 kHz and less than about 20 MHz. In one embodiment, the waves have a frequency between about 500 kHz and 20 MHz, and in another embodiment the waves have a frequency between about 1 MHz and 3 MHz. In yet another embodiment, the waves have a frequency of about 3 MHz.

The term "catheter" is used broadly, and encompasses its ordinary definition, as well as flexible tubes configured to be inserted into a body cavity, duct or vessel.

#### Overview of a Small Vessel Ultrasonic Catheter

FIGS. 1, 2A and 2B illustrate an exemplary embodiment of an ultrasonic catheter **100** that is particularly well-suited for use in small vessels of the distal anatomy, such as in small neurovascular vessels in the brain.

As illustrated in FIGS. 1 and 2A, the ultrasonic catheter **100** generally comprises a multi-component tubular body **102** having a proximal end **104** and a distal end **106**. The tubular body **102** and other components of the catheter **100** can be manufactured in accordance with conventional catheter manufacturing techniques. Suitable dimensions can be readily selected based on the dimensions of the treatment site and the desired percutaneous access site.

In an exemplary embodiment, the tubular body **102** is elongate and flexible, and comprises an outer sheath **108** (illustrated in FIG. 2A) that is positioned over an inner core **110**. For example, in embodiments particularly well-suited for small neurovascular vessels, the outer sheath **108** can comprise extruded polytetrafluoroethylene ("PTFE"), polyetheretherketone ("PEEK"), polyethylene ("PE"), polyimides, braided polyimides and/or other similar materials. In such embodiments, the outer sheath **108** has an outer diameter of approximately 0.039 inches at its proximal end and between approximately 0.033 and approximately 0.039 inches at its distal end. In such embodiments, the outer sheath **108** has an axial length of approximately 150 centimeters. In other embodiments, the outer sheath **108** can be formed from

a braided tubing comprising high or low density polyethylenes, urethanes, nylons, and so forth. Such configurations enhance the flexibility of the tubular body **102**. In still other embodiments, the outer sheath **108** can include a stiffening member (not shown) at the tubular body proximal end **104**.

The inner core **110** at least partially defines a central lumen **112**, or "guidewire lumen," which preferably extends through the length of the catheter **100**. The central lumen **112** has a distal exit port **114** and a proximal access port **116**. As best illustrated in FIG. 1, the proximal access port **116** is defined by therapeutic compound inlet port **117** on a back end hub **118**, which is attached to the outer sheath proximal end **104**. In the exemplary embodiment illustrated in FIG. 1, the back end hub **118** is attached to a control box connector **120**, which described in greater detail below.

In an exemplary embodiment, the central lumen **112** is configured to receive a guidewire (not shown) having a diameter of between approximately 0.010 inches to approximately 0.012 inches. In an exemplary embodiment, the inner core **110** is formed from polyimide or a similar material, which can optionally be braided to increase the flexibility of the tubular body **102**.

Referring now to the exemplary embodiment illustrated in FIGS. 2A and 2B, the distal end **106** of the tubular body **102** includes an ultrasound radiating member **124**. In the illustrated embodiment, the ultrasound radiating member **124** comprises an ultrasonic transducer, which converts, for example, electrical energy into ultrasonic energy.

In the embodiment illustrated in FIGS. 2A and 2B, the ultrasound radiating member **124** is in the shape of a hollow cylinder as is conventional in the prior art. Improved radiating members **124** will be described in FIGS. 12 through 17 below.

The inner core **110** extends through the ultrasound radiating member **124**, which is positioned over the inner core **110**. The ultrasound radiating member **124** can be secured to the inner core **110** in a suitable manner, such as with an adhesive. Extending the core through the member **124** advantageously provides enhanced cooling of the ultrasound radiating member **124**. Specifically, as will be explained in more detail below, a therapeutic compound can be injected through the central lumen **112**, thereby providing a heat sink for heat generated by the ultrasound radiating member **124**.

As described above, suitable operating frequencies for the ultrasound radiating member **124** include, but are not limited to, from about 20 kHz to less than about 20 MHz. In one embodiment, the frequency is between about 500 kHz and about 20 MHz, and in another embodiment the frequency is between about 1 MHz and about 3 MHz. In yet another embodiment, the ultrasonic energy has a frequency of about 3 MHz.

In the exemplary embodiment illustrated in FIGS. 2A and 2B, ultrasonic energy is generated by supplying electrical power to the ultrasound radiating member **124**. The electrical power can be supplied through the controller box connector **120**, which is connected to a first electrically conductive wire **126** and a second electrically conductive wire **128**. As illustrated, the wires **126**, **128** extend through the catheter body **102**. In such embodiments, the wires **126**, **128** are secured to the inner core **110**, lay along the inner core **110** and/or extend freely in the space between the inner core **110** and the outer sheath **108**. In the illustrated arrangement, the first wire **126** is connected to the hollow center of the ultrasound radiating member **124**, while the second wire **128** is connected to the outer periphery of the ultrasound radiating member **124**. In an exemplary embodiment, the ultrasound radiating member



**124** comprises a piezoelectric ceramic oscillator; in other embodiments, the ultrasound radiating member **124** comprises other similar materials.

In the modified embodiment, the catheter **10** may include more than one ultrasound radiating member **124**. In such an embodiment, the ultrasound radiating members may be electronically connected in series or parallel as described above and in more detail below.

Still referring to the exemplary embodiment illustrated in FIGS. 2A and 2B, the distal end of the catheter **100** includes sleeve **130**, which is generally positioned about the ultrasound radiating member **124**. In such embodiments, the sleeve **130** comprises a material that readily transmits ultrasonic energy. Suitable materials for the sleeve **130** include, but are not limited to, polyolefins, polyimides, polyesters and other low ultrasound impedance materials. Low ultrasound impedance materials are materials that readily transmit ultrasonic energy with minimal absorption of the ultrasonic energy. The proximal end of the sleeve **130** can be attached to the outer sheath **108** with an adhesive **132**. In a similar manner, the distal end of the sleeve **130** can be attached to a catheter tip **134**. In the illustrated arrangement, the tip **134** is generally rounded and is also attached to the distal end of the inner core **110**.

In an exemplary embodiment, the tubular body **102** is divided into at least three sections of varying stiffness. The first section, which includes the proximal end **104**, is generally more stiff than a second section, which lies between the proximal end **104** and the distal end **106**. This arrangement facilitates the movement and placement of the catheter **100** within small vessels. The third section, which includes ultrasound radiating element **124**, is generally stiffer than the second section due to the presence of the ultrasound radiating element **124**.

Still referring to the exemplary embodiment illustrated in FIG. 2B, the catheter **100** includes at least one temperature sensor **136** that is located at or near the distal end of the catheter **100**, and near the ultrasound radiating member **124**. Suitable temperature sensors include, but are not limited to, diodes, thermistors, thermocouples, resistance temperature detectors ("RTD"), and fiber optic temperature sensors that use thermochromic liquid crystals. In an exemplary embodiment, the temperature sensors are operatively connected to a control box (not shown) through a control wire that extends through the tubular body **102** and back end hub **118**, and that is operatively connected to a control box through the control box connector **120**. In such embodiments, the control box includes a feedback control system, such as the control system described herein. In an exemplary embodiment, the control box is configured to monitor and control the power, voltage, current and phase of the signal supplied to the ultrasound radiating members **124**. This configuration allows the temperature of the catheter to be monitored and controlled.

In an exemplary use, a free end of a guidewire is percutaneously inserted into the arterial system at a suitable insertion site. The guidewire is advanced through the vessels towards a treatment site, which includes, for example, a clot. In an exemplary embodiment, the guidewire is directed through the clot.

The catheter **100** is then percutaneously inserted through the insertion site and advanced along the guidewire towards the treatment site using conventional over-the-guidewire techniques. The catheter **100** is advanced until the distal end of the catheter **100** is positioned at or within the clot. In a modified embodiment, the catheter distal end includes radiopaque markers to aid in positioning the catheter at the treatment site.

The guidewire is then withdrawn from the central lumen **112**. A therapeutic compound solution source (not shown), such as a syringe with a Luer fitting, is attached to the therapeutic compound inlet port **117** and the control box connector **120** is connected to the control box. Thus, the therapeutic compound can be delivered through the central lumen **112** and the exit port **114** to the clot. Suitable therapeutic compounds for treating thrombus include, but are not limited to, aqueous solutions containing a thrombolytic agent (that is, a clot-dissolving drug), such as, heparin, urokinase, streptokinase, TPA and BB-10153, which is manufactured by British Biotech (Oxford, United Kingdom). In other embodiments, wherein the ultrasonic catheter is not used to remove a thrombus, other agents can be delivered through the central lumen. Such other agents include, but are not limited to, cancer treating drugs, genetic material, light activated drugs, and so forth.

The ultrasound radiating member **124** is activated to deliver ultrasonic energy through the distal end of the catheter **100** to the treatment site. As mentioned above, suitable frequencies for the ultrasound radiating member **124** include, but are not limited to, from about 20 kHz to less than about 20 MHz. In one embodiment, the frequency is between about 500 kHz and about 20 MHz, and in another embodiment the frequency is between about 1 MHz and about 3 MHz. In yet another embodiment, the ultrasonic energy has a frequency of about 3 MHz. The therapeutic compound and ultrasonic energy can be applied until the clot is partially or entirely dissolved. Once the clot has been dissolved to the desired degree, the catheter **100** can be withdrawn from the treatment site.

In a modified embodiment, the catheter **100** includes a cooling system for removing heat generated by the ultrasound radiating member **124**. In one such embodiment, a return path can be formed in region **138**, such that coolant from a coolant system can be directed through region **138** (see FIG. 2A).

#### Overview of a Long Segment Ultrasonic Catheter

FIGS. 3A and 3B illustrate one embodiment of an ultrasonic catheter **10**, which is particularly well-suited for treating long segment peripheral arterial occlusions, such as those occasionally found in the arteries of the leg.

As illustrated in FIG. 3A, the ultrasonic catheter **10** generally comprises a multi-component tubular body **12** having a proximal end **14** and a distal end **15**. The tubular body **12** and other components of the catheter **10** can be manufactured in accordance with any of a variety of conventional catheter manufacturing techniques. Suitable dimensions for the catheter components can be readily selected based on the natural and anatomical dimensions of the treatment site and of the desired percutaneous insertion site.

In an exemplary embodiment, the tubular body **12** is elongate and flexible, and comprises an outer sheath **16**. The outer sheath **16** preferably includes a support section **17** located at the proximal end and an energy delivery section **18** located at the distal end of the catheter **10**. In one embodiment, the support section **17** comprises extruded PTFE, PEEK, PE and/or similar materials that provide the outer sheath **16** with enough flexibility, kink resistance, rigidity and structural support necessary to push the energy delivery section **18** to a treatment site. In an embodiment particularly well-suited for treating thrombus in the arteries of the leg, the outer sheath **16** has an outside diameter of approximately 0.060 inches to approximately 0.075 inches. In such, an embodiment, the outer sheath **16** has an axial length of approximately 90 centimeters.

In an exemplary embodiment, the energy delivery section 18 of the outer sheath 16 comprises a relatively thin material compared to the support section 17. A thinner material advantageously increases the acoustic transparency of the energy delivery section 18. Suitable materials for the energy delivery section 18 include, but are not limited to, high or low density polyethylenes, urethanes, nylons, and so forth.

Referring now to the exemplary embodiments illustrated in FIGS. 3A and 3C, the outer sheath 16 defines a utility lumen 28 that extends through the length of the catheter 10. In the exemplary embodiment illustrated in FIG. 3A, the utility lumen 28 has a distal exit port 29 and a proximal access port 31. The proximal access port 31 is defined by a backend hub 33, which is attached to the proximal end of the outer sheath 16.

Still referring to FIG. 3A, a delivery lumen 30 is positioned adjacent the energy delivery section 18. The delivery lumen 30 includes an inlet port 32, which is formed in the backend hub 33 and is coupled to a therapeutic compound source via a hub such as a Luer type fitting. The delivery lumen 30 can be incorporated into the support section 17 (as illustrated in FIG. 3A) or can be external to the support section (as illustrated in FIG. 3C).

The catheter 10 also includes an elongated inner core 34 (see FIG. 3B) having a proximal end 36 and a distal end 38. An ultrasound radiating member 40 is positioned at or near the core distal end 38. Further information regarding methods and structures for mounting ultrasound radiating members within the inner core can be found in Applicant's co-pending U.S. patent application Ser. No. 10/309,388, which is hereby incorporated herein by reference in its entirety. For example, in an exemplary embodiment, a plurality of ultrasound radiating members, such as the ultrasound radiating members disclosed herein and illustrated in FIGS. 12 through 17, can be mounted within the inner core. In such embodiments, the ultrasound radiating members can be electrically connected in series or in parallel.

The inner core 34 has an outer diameter which permits the inner core 34 to be inserted into the utility lumen 28 via the proximal access port 31. FIG. 4A illustrates the inner core 34 inserted inside the utility lumen 28 with an ultrasound radiating member 40 is positioned within the energy delivery section 18. Suitable outer diameters of the inner core 34 include, but are not limited to, between approximately 0.010 inches and approximately 0.100 inches. Suitable diameters of the utility lumen 28 include, but are not limited to between approximately 0.015 inches and approximately 0.110 inches.

The ultrasound radiating member 40 can be rotated or moved within the energy delivery section 18 as illustrated by the arrows 52 in FIG. 4A. The ultrasound radiating member 40 can be moved within the energy delivery section 18 by manipulating the inner core proximal end 36 while holding the backend hub 33 stationary. The inner core 34 is at least partially constructed from a material that provides enough structural support to permit movement of the inner core 34 within the outer sheath 16 without causing the outer sheath 16 to kink. Suitable materials for the inner core 34 include, but are not limited to, polyimides, polyesters, polyurethanes, thermoplastics, elastomers, and braided wires with fiber reinforcement.

As illustrated in FIG. 4A, the outer diameter of the inner core 34 can be smaller than the inner diameter of the utility lumen 28, thereby creating a cooling fluid lumen 44 between the inner core 34 and the utility lumen 28. A cooling fluid can flow through the cooling fluid lumen 44, past the ultrasound radiating members 40 and through the distal exit port 29. Cooling fluid can be supplied via a cooling fluid fitting 46

provided on the backend hub 33 shown in FIG. 3A. The cooling fluid flow rate and/or the power to the ultrasound radiating members 40 can be adjusted to maintain the temperature of the ultrasound radiating member 40 within a specified range.

Referring now to FIG. 4B, the cooling fluid can be flowed from the cooling fluid fitting 46 through the cooling fluid lumen 44 as illustrated by arrows 48. The cooling fluid fitting 46 optionally includes a hemostasis valve 50 having an inner diameter that substantially matches the diameter of the inner core 34. The matched diameters reduce leaking of the cooling fluid between the cooling fluid fitting 46 and the inner core 34.

Referring now to the exemplary embodiment illustrated in FIG. 4C, the ultrasound radiating member 40 comprises a hollow cylinder, and the inner core 34 defines a central lumen 51, which extends through the ultrasound radiating member 40. In such embodiments, the cooling fluid flows through the central lumen 51, and past and through the ultrasound radiating member 40, thereby providing cooling to the ultrasound radiating member 40. In this configuration, the cooling fluid can be supplied via the proximal access port 31, with the cooling fluid fitting 46 and hemostasis valve 50 providing a seal between the inner core 34 and the outer sheath 16. In modified embodiments, the sheath 16 can be closed at the catheter distal end, thereby providing a system for recirculating cooling fluid, and for preventing cooling fluid from entering the patient's vascular system.

Referring again to the exemplary embodiment illustrated in FIG. 3A, the catheter 10 includes an occlusion device 22 positioned at the distal end of the catheter 10. In such embodiments, the utility lumen 28 extends through the occlusion device 22. The portion of the utility lumen 28 extending through the occlusion device 22 has a diameter that can accommodate a guidewire (not shown) but that prevents the ultrasound radiating member 40 from passing through the occlusion device 22. Suitable inner diameters for the occlusion device 22 include, but are not limited, to between approximately 0.005 inches and approximately 0.050 inches.

Referring now to the exemplary embodiment illustrated in FIG. 5A, the delivery lumen 30 includes a therapeutic compound delivery portion that is positioned adjacent the energy delivery section 18. As illustrated in FIG. 5B, in an exemplary embodiment, the delivery lumen 30 is wound around the tubular body 12 in the energy delivery section 18. In such embodiments, the delivery lumen 30 includes a series of delivery ports 58. A therapeutic compound source coupled to the inlet port 32 can provide a pressure which drives the therapeutic compound through the delivery lumen 30 and out the delivery ports 58. A suitable material for the delivery lumen 30 includes, but is not limited to, high or low density polyethylenes, urethanes, nylons, and so forth.

In modified embodiments, the catheter 10 can include a plurality of delivery lumens 30. The delivery lumens 30 can be wound around the energy delivery section 18 or they can be positioned along the length of the energy delivery section 18 as illustrated in FIGS. 5C and 5D. Each delivery lumen 30 can be coupled to the same drug inlet port 32, or each delivery lumen 30 can be coupled to an independent drug inlet port 32, thus allowing different therapeutic compound solutions to be delivered to different delivery ports 58.

In an exemplary embodiment, the delivery ports 58 are positioned close enough to achieve a substantially even flow of therapeutic compound solution around the circumference of the energy delivery section 18, and along the length of the energy delivery section 18. The proximity of adjacent delivery ports 58 can be changed by changing the density of delivery ports 58 along the delivery lumen 30, by changing

the number of windings of the delivery lumen 30 around the energy delivery section 18, or by changing the number of delivery lumens 30 positioned along the energy delivery section 18. In one embodiment, the windings of the delivery lumens 30 has a pitch that ranges from about one spiral per one centimeter to about one spiral per 20 centimeters.

The size of the delivery ports 58 can be the same or can vary along the length of the delivery lumen 30. For example, in one embodiment, the size of the delivery ports 58 along the distal portion of the energy delivery section 18 are larger than the delivery ports 58 along the proximal portion of the energy delivery section 18. The increase in size of the delivery ports 58 can be configured to produce similar flow rates of therapeutic compound solution through each delivery port 58. A similar flow rate increases the uniformity of therapeutic compound solution flow rate along the length of the outer sheath 16. In one embodiment in which the delivery ports 58 have similar sizes along the length of the delivery lumen 30, the delivery ports 58 have a diameter of between approximately 0.0005 inches and approximately 0.0050 inches. In another embodiment in which the size of the delivery ports 58 changes along the length of the delivery lumen 30, the delivery ports 58 have a diameter of between approximately 0.0001 inches and approximately 0.005 inches at the proximal end and between about 0.0005 inches and approximately 0.020 inches at the distal end. The increase in size between adjacent delivery ports 58 can be substantially uniform between along the delivery lumen 30. The dimensional increase of the delivery ports 58 can be dependent upon the material and the diameter of the delivery lumen 30. The delivery ports 58 can be punched, drilled, burnt with a laser, and so forth, into the delivery lumen 30.

Uniformity of the drug solution flow along the length of the outer sheath 16 can also be increased by increasing the density of the delivery ports 58 toward the distal end of the delivery lumen 30. Additionally, the delivery ports 58 can be slits with a straight shape (as illustrated in FIG. 5E) or an arcuate shape (as illustrated in FIG. 5F). The delivery lumen 30 can be constructed from materials such as polyimide, nylon, Pebax®, polyurethane or silicon. When the delivery lumen 30 contains drug solution, the slits remain closed until the pressure within the delivery lumen 30 exceeds a threshold pressure, where the pressure on each of the slit-shaped delivery ports 58 is approximately uniform. Once the threshold pressure is exceeded, the slit-shaped delivery ports 58 will open almost simultaneously, resulting in a nearly uniform flow of therapeutic compound solution from the slits. When the pressure in the delivery lumen 30 falls below the threshold pressure, the slit-shaped delivery ports 58 close and prevent delivery of additional therapeutic compound solution. Generally, the stiffer the material used to construct the delivery lumen 30, the higher the threshold pressure at which the slit-shaped delivery ports 58 will open. The slit shape can also prevent the delivery ports 58 from opening when exposed to low pressures from outside the outer sheath 16. As a result, slit shaped delivery ports 58 can enhance control of therapeutic compound delivery.

In the embodiment illustrated in FIG. 6A, the outer sheath 16 and energy delivery section 18 are constructed from a single material. Suitable materials include, but are not limited to, high or low density polyethylenes, urethanes, nylons, and so forth. The entire outer sheath 16, or only the outer sheath proximal end, can be reinforced by braiding, mesh or other constructions to increase the ability of the catheter to be pushed through a patient's vasculature ("pushability"). As illustrated in FIG. 6A, the delivery ports 58 can be incorporated into the outer sheath 16. The delivery ports 58 can be

coupled with independent delivery lumens 30 formed within the outer sheath 16, as illustrated in FIG. 6B.

In the exemplary embodiment illustrated in FIG. 7, the outer sheath 16 includes a support section 17 that is constructed from a different material than the energy delivery section 18. As mentioned above, the energy delivery section 18 can be constructed from a material which readily transmits ultrasound energy. The support section 17 can be constructed from a material which provides structural strength and kink resistance. Further, the support section 17, or the proximal end of the support section 17, can be reinforced by braiding, mesh or other constructions to increase kink resistance and pushability. Suitable materials for the support section 17 include, but are not limited to PTFE, PEEK, PE and/or similar materials. Suitable outer diameters for the support section 17 include, but are not limited to between approximately 0.020 inches and approximately 0.200 inches. Suitable materials for the energy delivery section 18 include, but are not limited to high or low density polyethylenes, urethanes, nylons, and other materials that produce minimal ultrasound attenuation. Such materials readily transmit ultrasound energy with minimal absorption of the ultrasound energy. FIG. 7 also illustrates an occlusion device 22 that is integrally formed with the energy delivery section 18.

#### Electrical Specifications

The foregoing electrical specification relate generally to both small vessel and long segment ultrasonic catheter. In the exemplary embodiments disclosed herein, the ultrasound radiating members comprise ultrasonic transducers configured to convert, for example, electrical energy into ultrasonic energy. An exemplary ultrasonic transducer for generating ultrasonic energy from electrical energy includes is a piezoelectric ceramic oscillator. In a modified embodiment, the ultrasonic energy can be generated by an ultrasonic transducer that is remote from the ultrasound radiating members, and the ultrasonic energy can be transmitted to the ultrasound radiating members via a wire, for example.

In an exemplary embodiment, the ultrasound radiating members comprise an ultrasonic transducer with a cylindrical shape. In other embodiments, the ultrasonic transducer can be a block, a hollow cylinder or a disk. The ultrasound radiating members can optionally be positioned concentrically around the inner core 34. In a modified embodiment, the ultrasound radiating members are formed of an array of smaller ultrasound radiating members. Similarly, a single ultrasound radiating member can be formed a combination of several smaller ultrasound radiating members.

As mentioned previously, suitable operating frequencies for the ultrasound radiating members include, but are not limited to, from about 20 kHz to less than about 20 MHz. In one embodiment, the frequency is between about 500 kHz and about 20 MHz, and in another embodiment the frequency is between about 1 MHz and about 3 MHz. In yet another embodiment, the ultrasonic energy has a frequency of about 3 MHz.

In embodiments wherein the catheter includes a plurality of ultrasound radiating members, ultrasound radiating member can be individually powered. For example, in one such embodiment, if the catheter includes  $n$  ultrasound radiating members, the catheter will also include  $2n$  wires to individually power  $n$  ultrasound radiating members. In other embodiments, the ultrasound radiating members 40 can be electrically coupled in serial or in parallel, as illustrated in FIGS. 8A and 8B. These arrangements permit more flexibility as they use fewer wires. Each of the ultrasound radiating members

can receive power simultaneously whether the ultrasound radiating members are in series or in parallel. When the ultrasound radiating members are connected in series, less current is required to produce the same power from each ultrasound radiating member than when the ultrasound radiating members are connected in parallel. The reduced current allows smaller wires to be used to provide power to the ultrasound radiating members, and accordingly increases the flexibility of the catheter. When the ultrasound radiating members are connected in parallel, an ultrasound radiating member can fracture or otherwise fail without breaking the current flow and interrupting the operation of the other ultrasound radiating members.

In an exemplary embodiment, the output power of the ultrasound radiating members can be controlled. For example, as illustrated in FIG. 8C, a common wire 61 can provide power of plurality of ultrasound radiating members 40, while each ultrasound radiating member 40 has its own return wire 62. A particular ultrasound radiating member 40 can be individually activated by closing a switch 64 to complete a circuit between the common wire 61 and the return wire 62 associated with the particular ultrasound radiating member 40. Once a switch 64 corresponding to a particular ultrasound radiating member 40 has been closed, the amount of power supplied to the ultrasound radiating member 40 can be adjusted using a potentiometer 66. Accordingly, a catheter with n ultrasound radiating members 40 uses only n+1 wires, and still permits independent control of the ultrasound radiating members 40. This reduced number of wires increases the flexibility of the catheter. To further improve the flexibility of the catheter, the individual return wires 62 can have diameters which are smaller than the common wire 61 diameter. For instance, in an embodiment where n ultrasound radiating members are powered simultaneously, the diameter of the individual return wires 62 can be approximately the square root of n times smaller than the diameter of the common wire 61.

As illustrated in the exemplary embodiment illustrated in FIG. 3B, the catheter further includes one or more temperature sensors 20 located at the catheter distal end. (The small vessel catheter illustrated in FIG. 2B also optionally includes a temperature sensor 136.) In such embodiments, the inner core proximal end 36 includes a temperature sensor lead 24, which is operatively connected to the temperature sensors 20. In the modified embodiment illustrated in FIG. 3C, the temperature sensors 20 are positioned in the energy delivery section 18 on the surface of the outer sheath 16. In such embodiments, the temperature sensor lead 24 extends from the outer sheath proximal end. Suitable temperature sensors 20 include, but are not limited to, temperature sensing diodes, thermistors, thermocouples, RTDs, and fiber optic temperature sensors which use thermochromic liquid crystals. Suitable temperature sensor 20 geometries include, but are not limited to, a point, patch, a stripe, and a band around the outer sheath 16. The temperature sensors 20 can be positioned on the outer sheath 16 or on the inner core 34 near the ultrasound radiating members 40. In an exemplary embodiment, the temperature sensors 20 are positioned near the energy delivery section 18.

The temperature sensors 20 can be electrically connected as illustrated in FIG. 9. Each temperature sensor 20 can be coupled with a common wire 61 and an individual return wire 62. Accordingly, n+1 wires can be used to independently sense the temperature at n temperature sensors 20. The temperature at a particular temperature sensor 20 can be determined by closing a switch 64 to complete a circuit that includes the particular temperature sensor 20. When the tem-

perature sensors 20 are thermocouples, the temperature can be calculated from the voltage in the circuit using, for example, a sensing circuit 63. To improve the flexibility of the outer sheath 16, the individual return wires 62 can have diameters which are smaller than the diameter of the common wire 61.

Each temperature sensor 20 can also be independently wired. In such embodiments, n independently wired temperature sensors 20 use 2n wires along the outer sheath 16.

The flexibility of the outer sheath 16 and inner core 34 can also be improved by using fiber optic based temperature sensors 20. Particularly, in such embodiments only n fiber optics are used to sense the temperature at n temperature sensors 20.

The catheter 10 can be used with a feedback control system 68, as illustrated in FIG. 10. In such embodiments, the temperature at each temperature sensor 20 is monitored, and the output power of the energy source 70 is adjusted accordingly. The physician can, if desired, override the closed or open loop system.

In the exemplary embodiment illustrated in FIG. 10, the feedback control system 68 includes an energy source 70, a power circuit 72, and a power calculation device 74 coupled with the ultrasound radiating members 40. A temperature measurement device 76 is coupled with the temperature sensors 20 on the outer sheath 16 or the inner core 34. A processing unit 78 is coupled with the power calculation device 74, the power circuits 72, and a user interface and display 80.

In operation, the temperature at the temperature sensors 20 is determined at the temperature measurement device 76. The processing unit 78 receives the determined temperatures from the temperature measurement device 76. The determined temperatures can then be displayed to the user at the user interface and display 80.

The processing unit 78 includes logic for generating a temperature control signal. The temperature control signal is proportional to the difference between the measured temperature and a desired temperature. The desired temperature can be determined by the user or be preset within the processing unit 78. For example, in an exemplary embodiment, the user sets the desired temperature using the user interface and display 80.

The temperature control signal is received by the power circuit 72. The power circuit 72 can be configured to adjust the power level, voltage, phase and/or current of the energy supplied to the ultrasound radiating members 40 from the energy source 70. For instance, when the temperature control signal is above a particular level, the power supplied to a particular ultrasound radiating member 40 can be reduced in response to the temperature control signal. Similarly, when the temperature control signal is below a particular level, the power supplied to a particular ultrasound radiating member 40 can be increased in response to the magnitude of the temperature control signal. After each power adjustment, the processing unit 78 monitors the temperature sensors 20 and produces another temperature control signal which is received by the power circuits 72.

The processing unit 78 can also include safety control logic. The safety control logic detects when the temperature at a temperature sensor 20 has exceeded a safety threshold. The processing unit 78 can then provide a temperature control signal which causes the power circuit 72 to reduce or stop the delivery of energy from the energy source 70 to the ultrasound radiating members 40.

Because the ultrasound radiating members 40 can move relative to the temperature sensors 20 in certain embodiments, it can be unclear which ultrasound radiating member

should have a power, voltage, phase and/or current level adjustment. Consequently, each ultrasound radiating member 40 is identically adjusted in one embodiment. In a modified arrangement, the power, voltage, phase, and/or current supplied to each of the ultrasound radiating members 40 is adjusted in response to the temperature sensor 20 which indicates the highest temperature. Making voltage, phase and/or current adjustments in response to the temperature of the temperature sensor 20 indicating the highest temperature can reduce the likelihood that the treatment site overheats.

The processing unit 78 can be configured to receive a power signal from the power calculation device 74. The power signal can be used to determine the power being received by each ultrasound radiating member 40. The determined power can then be displayed to the user on the user interface and display 80.

The feedback control system 68 can maintain the treatment site within a desired temperature range. For example, to prevent the temperature of the treatment site from increasing more than 6° C. above body temperature, and thus causing tissue damage, the ultrasound radiating members 40 can be independently monitored and controlled as described above. In one embodiment, the processing unit 78 can be preprogrammed to drive each ultrasound radiating member 40 at a predetermined energy for a predetermined length of time.

The processing unit 78 can comprise a digital or analog controller, or a computer with software. In embodiments wherein the processing unit 78 is a computer, it can include a central processing unit coupled through a system bus. The user interface and display 80 can comprise a mouse, keyboard, a disk drive or other non-volatile memory system, a display monitor, and other peripherals. Program memory and data memory can also be coupled to the bus.

In lieu of the series of power adjustments described above, a profile of the power to be delivered to each ultrasound radiating member 40 can be incorporated in the processing unit 78. A preset amount of energy to be delivered can also be profiled. The power delivered to each ultrasound radiating member 40 can be adjusted according to the profiles.

#### Methods of Use

FIGS. 11A through 11G illustrate an exemplary method for using the ultrasonic catheter 10. This method is applicable to both long segment and small vessel catheters. In FIG. 11A, a guidewire 84 similar to a guidewire used in typical angioplasty procedures is directed through vessels 86 toward a treatment site 88 which includes a clot 90. The guidewire 84 is optionally directed through the clot 90. Suitable vessels include, but are not limited to, the large periphery blood vessels of the body. Of course, as mentioned above, the ultrasonic catheter 10 can also be used for various imaging applications and for treating and/or diagnosing other diseases in other body parts.

In FIG. 11B, the outer sheath 16 is advanced over the guidewire 84 using over-the-guidewire techniques. The outer sheath 16 is advanced until the energy delivery section 18 is positioned at the clot 90. Radiopaque markers are optionally positioned at the energy delivery section 18 of the outer sheath 16 to aid in the positioning of the outer sheath 16 within the treatment site 88.

Referring now to FIG. 11C, the guidewire 84 is withdrawn from the utility lumen 28 by pulling the guidewire 84 proximally while holding the outer sheath 16 stationary.

In FIG. 11D, a temperature monitor 92 is coupled with the temperature sensor leads 24, a cooling fluid source 94 is coupled with the cooling fluid fitting 46, and a therapeutic

compound solution source 96 is coupled with the inlet port 32. The therapeutic compound solution source 96 can be a syringe with a Luer fitting that is complementary to the inlet port 32. Pressure can be applied to a plunger 98 on the therapeutic compound solution source 96, thereby driving the therapeutic compound through the delivery lumen 30. The therapeutic compound is delivered from the delivery lumen 30 through the delivery ports 58 as illustrated by the arrows 99 in FIG. 11E. Suitable therapeutic compounds include, but are not limited to, an aqueous solution containing a thrombolytic agent (that is, a clot-dissolving drug), such as, heparin, urokinase, streptokinase, TPA and BB-10153. In other embodiments, wherein the ultrasonic catheter is not used to remove a thrombus, other therapeutic compounds (such as cancer treating drugs, genetic material, light activated drugs and so forth) can be delivered through the delivery lumen.

Referring now to FIG. 11F, in embodiments wherein the ultrasound radiating member 40 is movable with respect to the utility lumen 28, the inner core 34 is inserted into the utility lumen 28 until the ultrasound radiating member 40 is positioned within the energy delivery section 18. To aid in positioning the ultrasound radiating member 40, radiopaque markers can be affixed to the inner core 34 adjacent the ultrasound radiating members 40, or the ultrasound radiating members 40 themselves can be radiopaque. In a modified embodiment, the ultrasonic energy radiated by the ultrasound radiating members 40 can be used to aid placement. Once the inner core 34 is properly positioned, the ultrasound radiating member 40 is activated to deliver ultrasonic energy through the energy delivery section 18 to the clot 90. In one embodiment, the ultrasonic energy has a frequency between approximately 20 kHz and approximately 20 MHz. In another embodiment, the frequency is between about 500 kHz and about 20 MHz. In another embodiment, the frequency is between about 1 MHz and about 3 MHz. In another embodiment, the frequency is about 3 MHz. While the ultrasonic energy is being delivered, the ultrasound radiating member 40 can optionally be moved within the energy delivery section 18 as illustrated by the arrows 52. The ultrasound radiating member 40 can be moved within the energy delivery section 18 by manipulating the inner core proximal end 36 while holding the backend hub 33 stationary. In the illustrated embodiment, a cooling fluid flows through the cooling fluid lumen 44 and out the occlusion device 22.

The cooling fluid can be delivered before, after, during or intermittently with the delivery of the ultrasonic energy. Similarly, the therapeutic compound can be delivered before, after, during or intermittently with the delivery of ultrasonic energy. As a result, the acts illustrated in FIGS. 11A through 11F can be performed in different orders than are described above. The therapeutic compound and energy are applied until the clot 90 is partially or entirely dissolved, as illustrated in FIG. 11G. Once the clot 90 has been sufficiently dissolved, the outer sheath 16 and inner core 34 are withdrawn from the treatment site 88.

Further information regarding other techniques for treating a clot using ultrasonic energy delivered from a catheter can be found in Applicant's co-pending U.S. patent application Ser. No. 09/107,078, which is hereby incorporated herein by reference in its entirety.

#### Ultrasound Radiating Members

##### Structures

A wide variety of ultrasound radiating member configurations can be used with the catheters described above. As

evident from the foregoing description, in certain embodiments the ultrasound radiating members comprise an elongate cylinder of piezoelectric material having a hollow core through which materials such as a cooling fluid, a therapeutic compound, or electrical conductors can be passed. Such ultrasound radiating member embodiments can be used with both long segment and small vessel ultrasonic catheters.

Exemplary embodiments of an ultrasound radiating member **200** are illustrated in FIGS. **12A** through **12E**. In these embodiments, the ultrasound radiating member **200** comprises a front face **202**, a rear face (not shown) that is opposite the front face, and a hollow central core **204** that extends along the longitudinal axis of the ultrasound radiating member **200**. In such embodiments, the front and rear faces form an n-sided polygon. For example, in FIG. **12A**, the front and rear faces have five sides and form a pentagon. In FIG. **12B**, the front and rear faces have six sides and form a hexagon. In FIG. **12C**, the front and rear faces have eight sides and form an octagon. In FIG. **12D**, the front and rear faces have three sides and form a triangle. In FIG. **12E**, the front and rear faces have four sides and form a square. In these embodiments, the sides of the front and rear faces are connected by generally rectangular side faces **206**, which together form the outer surface of the ultrasound radiating member **200**.

As described herein, in an exemplary embodiment the ultrasound radiating member **200** comprises a piezoelectric ceramic or a similar material. In one embodiment, illustrated in FIG. **13**, the side faces **206** and the central core **204** are coated with a conductive material. The conductive material can be applied using an appropriate application technique, such as electroplating. A first wire **208** is attached to the central core **204**, and a second wire **210** is connected to at least one of the side faces **206**. In such embodiments, application of a voltage difference **212** across the first and second wires causes the ultrasound radiating member **200** to generate ultrasonic energy.

In a modified embodiment, the ultrasound radiating member **200** is mounted directly on an elongate member that extends through the central core **204**. This configuration is particularly advantageous in applications where a plurality of ultrasound radiating members are to be mounted within the inner core **34**, as disclosed herein and as illustrated in FIGS. **3B** and **4A**. The ultrasound radiating members can be electrically connected in series or in parallel. For example, in an embodiment wherein the ultrasound radiating members are electrically connected in parallel, a common wire runs through, and is electrically connected to, the centers of several ultrasound radiating members, and a second wire runs along, and is electrically connected to, the side faces of the ultrasound radiating members. In an embodiment wherein the ultrasound radiating members are electrically connected in series, an electrically insulating core runs through the centers of several ultrasound radiating members, and a wire connects the inner electrode and the outer electrode of adjacent ultrasound radiating members. In still other embodiments, the ultrasound radiating members can be electrically grouped, such that a separate groups of ultrasound radiating members can be individually activated.

The embodiments disclosed herein advantageously allow a plurality of ultrasound radiating members to be mounted within an inner core **34** that is configured to be inserted into the tubular body of an ultrasonic catheter. The ultrasound radiating members illustrated in FIGS. **12A** through **12E** are particularly well suited for such applications, because structural members, electrical members, and/or fluids can be passed through the central core **204**.

The ultrasound radiating members **200** illustrated in FIGS. **12A** through **12E** have several advantages. For example, such ultrasound radiating members **200** have more radiating faces and thus produce a more radially uniform distribution of ultrasound energy as compared to a rectangular block or flat plate. Moreover, as compared to cylindrical ultrasound members, the ultrasound radiating members **200** described herein have a larger output region and have lower mechanical stresses during operation. Lower mechanical stresses during operation result in lower failure rates.

Although not illustrated, modified embodiments of the ultrasound radiating members **200** have side faces **206** that are non-rectangular (for example, square or tapered) and/or not identical.

## Ultrasound Radiating Members

### Manufacturing Techniques

Improved methods for manufacturing ultrasound radiating members, including the ultrasound radiating members illustrated in FIGS. **12A** through **12E** are described herein.

As illustrated in FIG. **14**, a sheet **214** of piezoelectric ceramic or similar material is provided. In an exemplary embodiment, the sheet **214** has a thickness  $t$  that is greater than the length of the finished ultrasound radiating member. A plurality of holes **216** are then drilled into the sheet **214**. In an exemplary embodiment, the holes **216** are drilled in a uniform pattern. In one embodiment, the holes **216** are through holes, which extend through the sheet **214**. In another embodiment, the holes **216** are blind holes that do not extend through the sheet **214**. In exemplary embodiments wherein the holes **216** are blind holes, the blind holes are drilled to a depth that is greater than the length of the finished ultrasound radiating member.

Referring now to FIGS. **15A** and **15B**, in an exemplary embodiment, the perforated sheet **214** is then diced with a dicing blade or other precision cutting tool to produce an n-sided polygonal geometry. For example, in FIG. **15A**, a pattern of cuts **218** are used to produce a hexagonal ultrasound radiating member **220** centered about each hole **216**. In FIG. **15B**, the pattern of cuts **218** produces an octagonal ultrasound radiating member **222** that is centered about each hole **216**. In other embodiments, the cuts **218** can be arranged to form other polygons with more or fewer sides, such as, triangles, squares, and pentagons. The triangular geometry, illustrated in FIG. **12D**, is particularly advantageous because it requires a minimum number of cuts while producing no wasted piezoelectric material.

In an exemplary embodiment, the cuts **218** do not extend through the piezoelectric sheet **214**. However, in other embodiments, the cuts **218** do extend through the piezoelectric sheet **214**. For example, as illustrated in FIG. **16**, in a first region **226**, the cuts **218** extend through the piezoelectric sheet **214**; in a second region **228**, the cuts **218** do not extend through the piezoelectric sheet **214**. In embodiments wherein the cuts **218** do not extend through the piezoelectric sheet **214**, the holes **216** (illustrated in FIG. **14**) can be drilled deeper than the cuts **218**.

Still referring to FIG. **16**, after the cuts **218** are made, the upper surface of the sheet, which includes the interior surfaces of the holes **216** and the interior surfaces of the cuts **218**, are plated with a conductive coating. This plating process provides a conductive coating on the central core **204** and the side faces **206** of the ultrasound radiating members to be harvested from the piezoelectric sheet. In such embodiments, plating material deposited on the top surface **224** of the sheet

19

(that is, on the front or rear faces of the ultrasound radiating members **200**) can be removed using a grinding wheel **230**, by milling, or using other methods (for example, by grit blasting).

Referring now to FIG. 17, in an exemplary embodiment, the individual ultrasound radiating members are harvested by using a dicing blade **232** or other precision cutting tool to separate uncut backside material **234** from the cut ultrasound radiating members **200**. In one embodiment, illustrated in FIG. 17, the dicing blade **232** cuts at an angle that is substantially perpendicular to the longitudinal axis of the holes **216**. In the exemplary embodiment illustrated in FIG. 17, the sheet **214** is placed upright, and is cut vertically downward, such that the cut ultrasound radiating members **200** can be caught and removed without being damaged by the dicing blade **232**. In such embodiments, the dicing blade cut intersects the cuts **218** and the holes **216**, thereby producing finished ultrasound radiating members as illustrated in FIGS. 12A through 12E.

The methods for manufacturing ultrasound radiating members disclosed herein have several advantages. For example, ultrasound radiating members having the configurations disclosed herein subject the piezoelectric material to reduced mechanical stresses during use, which decreases the likelihood of fracture and grain disruption as compared to conventionally manufactured ultrasound radiating members. Furthermore, the polygonal ultrasound radiating members described herein emit ultrasonic energy around a larger effective area, and with an improved output pattern, as compared to conventional cylindrical ultrasound radiating members. The methods disclosed herein are also less complex and less expensive than conventional machining methods. These methods are also particularly useful for manufacturing miniaturized ultrasonic elements.

#### SCOPE OF THE INVENTION

While the foregoing detailed description discloses several embodiments of the present invention, it should be understood that this disclosure is illustrative only and is not limiting of the present invention. It should be appreciated that the

20

specific configurations and operations disclosed can differ from those described above, and that the methods described herein can be used to manufacture non-piezoelectric components, and yet remain within the scope of the present invention. Thus, the present invention is to be limited only by the following claims.

I claim:

1. A method for manufacturing an ultrasonic catheter comprising:

- providing a sheet of piezoelectric material;
- drilling a plurality of holes into the piezoelectric material, each hole having an inner surface;
- making a plurality of cuts into the sheet, each cut having a depth less than the depth of the holes, the cuts forming an elongate polygon that is generally centered about one of the holes, the polygon having an outer surface;
- plating at least a portion of the inner and outer surfaces with a conductive material;
- cutting a backside from the sheet so as to separate a plurality of individual elongate piezoelectric polygons; and
- disposing at least one of the individual elongate piezoelectric polygons within a tubular catheter body.

2. The method of claim 1, wherein the backside is cut substantially parallel to a top surface of the sheet of piezoelectric material.

3. The method of claim 1, wherein the holes are cut through the piezoelectric material.

4. The method of claim 1, wherein the holes are blind holes that do not pass through the piezoelectric material.

5. The method of claim 1, wherein a plurality of elongate piezoelectric polygons are mounted on a central core configured to be disposed within the tubular catheter body.

6. The method of claim 5, further comprising electrically connecting the piezoelectric polygons in series.

7. The method of claim 1, wherein a plurality of elongate piezoelectric polygons are mounted on an electrically conductive central core configured to be disposed within the tubular catheter body.

\* \* \* \* \*

专利名称(译)	用于导管的超声辐射构件		
公开(公告)号	<a href="#">US7818854</a>	公开(公告)日	2010-10-26
申请号	US12/371544	申请日	2009-02-13
申请(专利权)人(译)	EKOS CORPORATION		
当前申请(专利权)人(译)	EKOS CORPORATION		
[标]发明人	WILSON RICHARD R		
发明人	WILSON, RICHARD R.		
IPC分类号	H04R17/10 A61B17/22 A61M25/00 A61M37/00		
CPC分类号	A61B17/2202 A61M37/0092 A61B2017/22002 A61B2017/22082 A61M25/0043 Y10T29/49002 Y10T29/49798 Y10T29/42 Y10T29/49005 Y10T29/49156 A61M2025/0057		
优先权	60/418400 2002-10-14 US		
其他公开文献	US20090144955A1		
外部链接	<a href="#">Espacenet</a> <a href="#">USPTO</a>		

#### 摘要(译)

一种方法包括提供具有顶表面的基本上平面的压电材料板。该方法还包括通过顶表面钻入多个孔并进入板坯。该方法还包括通过顶表面和平板制造多个切口。切口形成多个多边形，这些多边形通常以其中一个孔为中心。该方法还包括用导电材料电镀板坯。该方法还包括从板的顶表面移除导电材料。该方法还包括基本上平行于顶表面切割板坯。

